RJFSA
PBE icon

Raymond James Financial Services Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.41M Buy
20,156
+344
+2% +$23.8K ﹤0.01% 1934
2024
Q2 		$1.28M Buy
19,812
+845
+4% +$53.5K ﹤0.01% 1924
2024
Q1 		$1.23M Buy
18,967
+2,118
+13% +$138K ﹤0.01% 1939
2023
Q4 		$1.11M Sell
16,849
-398
-2% -$23.1K ﹤0.01% 1917
2023
Q3 		$984K Sell
17,247
-125
-0.7% -$7.62K ﹤0.01% 1921
2023
Q2 		$1.06M Buy
17,372
+943
+6% +$58.8K ﹤0.01% 1898
2023
Q1 		$1.03M Buy
16,429
+382
+2% +$24.6K ﹤0.01% 1880
2022
Q4 		$1.02M Buy
16,047
+1,558
+11% +$98.8K ﹤0.01% 1830
2022
Q3 		$854K Buy
14,489
+10,039
+226% +$619K ﹤0.01% 1911
2022
Q2 		$257K Sell
4,450
-1,337
-23% -$77K ﹤0.01% 2700
2022
Q1 		$359K Sell
5,787
-1,018
-15% -$62.1K ﹤0.01% 2581
2021
Q4 		$485K Sell
6,805
-555
-8% -$40.2K ﹤0.01% 2385
2021
Q3 		$551K Buy
7,360
+651
+10% +$49.6K ﹤0.01% 2309
2021
Q2 		$519K Buy
6,709
+387
+6% +$28.8K ﹤0.01% 2345
2021
Q1 		$467K Sell
6,322
-91
-1% -$6.88K ﹤0.01% 2335
2020
Q4 		$450K Sell
6,413
-900
-12% -$57K ﹤0.01% 2204
2020
Q3 		$414K Sell
7,313
-2,519
-26% -$148K ﹤0.01% 2093
2020
Q2 		$573K Sell
9,832
-1,560
-14% -$85K ﹤0.01% 1826
2020
Q1 		$530K Buy
11,392
+3,333
+41% +$174K ﹤0.01% 1514
2019
Q4 		$450K Sell
8,059
-1,800
-18% -$93.8K ﹤0.01% 2056
2019
Q3 		$467K Sell
9,859
-225
-2% -$11.5K ﹤0.01% 1947
2019
Q2 		$540K Sell
10,084
-1,104
-10% -$57.3K ﹤0.01% 1877
2019
Q1 		$617K Sell
11,188
-680
-6% -$36K ﹤0.01% 1750
2018
Q4 		$559K Buy
11,868
+765
+7% +$39.3K ﹤0.01% 1605
2018
Q3 		$660K Buy
11,103
+202
+2% +$11.8K ﹤0.01% 1722
2018
Q2 		$596K Sell
10,901
-1,850
-15% -$94.1K ﹤0.01% 1758
2018
Q1 		$628K Sell
12,751
-3,523
-22% -$180K ﹤0.01% 1582
2017
Q4 		$767K Sell
16,274
-11,596
-42% -$544K ﹤0.01% 1464
2017
Q3 		$1.39M Buy
27,870
+6,549
+31% +$311K 0.01% 1101
2017
Q2 		$974K Buy
21,321
+14,750
+224% +$637K 0.01% 1285
2017
Q1 		$278K Sell
6,571
-253
-4% -$10.6K ﹤0.01% 1943
2016
Q4 		$265K Buy
6,824
+147
+2% +$5.93K ﹤0.01% 1872
2016
Q3 		$280K Buy
6,677
+30
+0.5% +$1.23K ﹤0.01% 1831
2016
Q2 		$246K Buy
6,647
+470
+8% +$18.4K ﹤0.01% 1847
2016
Q1 		$236K Sell
6,177
-4,150
-40% -$161K ﹤0.01% 1681
2015
Q4 		$522K Sell
10,327
-854
-8% -$42.2K 0.01% 1184
2015
Q3 		$511K Buy
+11,181
New +$625K 0.01% 1040

Other funds holding PBE

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Raymond James Financial Services Advisors's PBE Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Invesco Biotechnology & Genome ETF (PBE) stake by 1.7% in Q3 2024, buying an estimated $23.8K and bringing the position to 20,156 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

Raymond James Financial Services Advisors first reported a position in PBE in Q3 2015 and has held it in 37 quarters since. 102 funds tracked by Wall St. Rank hold PBE as of Q3 2024.

  • Raymond James Financial Services Advisors held 20,156 shares of Invesco Biotechnology & Genome ETF worth $1.41M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 344 Invesco Biotechnology & Genome ETF shares in Q3 2024, an estimated $23.8K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1934 holding.
  • Raymond James Financial Services Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q3 2015 and has held it in 37 quarters since.
  • 102 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.